INHALED BECLOMETHASONE TO PREVENT CHRONIC LUNG DISEASE

本研究旨在阐明新生儿 慢性肺部疾病的发生，并测试吸入的容量和安全性 糖皮质激素预防慢性肺部疾病的过程及其 对生长和发育的伴随影响。这将是完成 通过一项随机、安慰剂对照的临床试验， 皮质类固醇，丙酸倍氯米松，用于小于1251克的婴儿 出生体重和小于33周的妊娠，在3至14天， 年龄，继续需要机械通气。 倍氯米松将 使用麻醉袋通过手动通气进行给药， 具有喷雾器装置的定量吸入器，治疗期为28天。

This study has been designed to elucidate mechanisms by which neonatal chronic lung disease occurs and to test the capacity and safety of inhaled glucocorticoid to prevent the process of chronic lung disease and its accompanying effects on growth and developement. This will be accomplished through a randomized, placebo controlled clinical trial of inhaled corticosteroid, beclomethasone dipropionate, in infants less than 1251 gm birth weight and less than 33 weeks gestation who, at 3 to 14 days of age, continue to require mechanical ventilation. Beclomethasone will be administered via manual ventilation with an anesthesia bag using a metered dose inhaler with a spacer device for a 28-day treatment period.